These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9641307)

  • 1. Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferon.
    Fukuda M; Chayama K; Tsubota A; Kobayashi M; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    J Gastroenterol Hepatol; 1998 Apr; 13(4):412-8. PubMed ID: 9641307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino acid substitutions in NS5A region of GB virus C and response to interferon therapy.
    Kato T; Mizokami M; Orito E; Ohba K; Nakano T; Kondo Y; Tanaka Y; Ueda R; Mukaide M; Yasuda K; Iino S
    J Med Virol; 1999 Apr; 57(4):376-82. PubMed ID: 10089050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.
    Ukai K; Ishigami M; Yoshioka K; Kawabe N; Katano Y; Hayashi K; Honda T; Yano M; Goto H
    World J Gastroenterol; 2006 Jun; 12(23):3722-8. PubMed ID: 16773689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
    Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
    Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients.
    Nagayama K; Enomoto N; Izumi N; Kurosaki M; Miyasaka Y; Watanabe H; Itakura J; Chen CH; Tazawa J; Hoshino Y; Ikeda T; Marumo F; Sato C
    Gut; 2001 Jun; 48(6):830-5. PubMed ID: 11358904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
    Gervain J; Czibula A; Simon J; Kalmár T
    Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection.
    Yoshioka K; Ito H; Watanabe K; Yano M; Ishigami M; Mizutani T; Sasaki Y; Goto H
    J Viral Hepat; 2005 Mar; 12(2):139-45. PubMed ID: 15720528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
    Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
    Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy.
    Chayama K; Suzuki F; Tsubota A; Kobayashi M; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Takahashi N; Kinoshita M; Kumada H
    Hepatology; 2000 Nov; 32(5):1138-44. PubMed ID: 11050067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
    Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
    J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment.
    Bellobuono A; Mondazzi L; Tempini S; Silini E; Idéo G
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1169-77. PubMed ID: 9471022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
    Miyasaka A; Kumagai I; Abe K; Suzuki K
    Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Method to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy.
    Nishiguchi S; Ueda T; Itoh T; Enomoto M; Tanaka M; Tatsumi N; Fukuda K; Tamori A; Habu D; Takeda T; Otani S; Shiomi S
    Hepatology; 2001 Jan; 33(1):241-7. PubMed ID: 11124842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.
    Enomoto N; Sakuma I; Asahina Y; Kurosaki M; Murakami T; Yamamoto C; Ogura Y; Izumi N; Marumo F; Sato C
    N Engl J Med; 1996 Jan; 334(2):77-81. PubMed ID: 8531962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.